Sort   by:  
 Page size 
TranscriptomicsTranscriptomic Comparison of Neuronal Development Stages using Induced Pluripotent Stem Cells from Bipolar Disorder Patients
Fibroblasts from patients with Type I bipolar disorder (BPD) and their unaffected siblings were obtained from an Old Order Amish pedigree with a high incidence of BPD and reprogrammed to induced pluripotent stem cells (iPSCs). Established iPSCs were subsequently differentiated into neuroprogenitors ...
ORGANISM(S): Homo sapiens 
2015-10-26 | E-GEOD-74358 | biostudies-arrayexpress
ProteomicsOrbitrap: narrow-range, defined mixtures for quantitative proteomics (PubMed ID: 23879310)
These six Orbi replicates of samples A and B represent 36 proteins from the Sigma UPS1 that have been mixed in defined concentrations that span a narrow dynamic range. These "NRD A" and "NRD B" mixtures have, in turn, been spiked into Agilent Pyrococcus furiosus lysate.
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) Pyrococcus Furiosus (ncbitaxon:2261) 
2014-01-10 | MSV000078522 | MassIVE
ProteomicsOrbitrap Velos: narrow-range, defined mixtures for quantitative proteomics (PubMed ID: 23879310)
These five Orbi Velos replicates of samples A and B represent 36 proteins from the Sigma UPS1 that have been mixed in defined concentrations that span a narrow dynamic range. These "NRD A" and "NRD B" mixtures have, in turn, been spiked into Agilent Pyrococcus furiosus lysate.
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) Pyrococcus Furiosus (ncbitaxon:2261) 
2014-01-10 | MSV000078521 | MassIVE
UnknownRibosomal protein SA haploinsufficiency in humans with isolated congenital asplenia.
Not available
S-EPMC3677541 | biostudies-literature
UnknownIntelectin-1 binds and alters the localization of the mucus barrier-modifying bacterium Akkermansia muciniphila.
Not available
S-EPMC9683900 | biostudies-literature
UnknownSingle-cell multi-omics analysis of the immune response in COVID-19.
Not available
S-EPMC8121667 | biostudies-literature
UnknownTocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8084355 | biostudies-literature
UnknownNeutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Not available
S-EPMC9757903 | biostudies-literature
UnknownAntibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Not available
S-EPMC8927425 | biostudies-literature
UnknownStratified analyses refine association between TLR7 rare variants and severe COVID-19.
Not available
S-EPMC11320601 | biostudies-literature
Sort   by:  
 Page size